Safety of the combination of chloroquine healthy adult men with G6PD deficiency Faso

被引：47

作者：

Mandi, G

Witte, S

Meissner, P

Coulibaly, B

Mansmann, U

Rengelshausen, J

Schiek, W

Jahn, A

Sanon, M

Wüst, K

Walter-Sack, I

Mikus, G

Burhenne, J

Riedels, KD

Schirmer, H

Kouyaté, B

Müller, O

机构：

[1] Univ Heidelberg, Dept Trop Hyg & Publ Hlth, D-69120 Heidelberg, Germany

[2] Univ Heidelberg, Inst Med Biometr & Informat, D-69120 Heidelberg, Germany

[3] Univ Heidelberg, Dept Pediat 4, D-69120 Heidelberg, Germany

[4] Univ Heidelberg, Dept Internal Med 6, D-69120 Heidelberg, Germany

[5] DSM Fine Chem, A-4021 Linz, Austria

[6] Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany

[7] Nouna Hlth Res Ctr, Nouna, Burkina Faso

来源：

TROPICAL MEDICINE & INTERNATIONAL HEALTH | 2005年 / 10卷 / 01期

关键词：

methylene blue; malaria; G6PD deficiency; Africa;

D O I：

10.1111/j.1365-3156.2004.01356.x

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

New drug combinations against falciparum malaria which are both effective and affordable for Sub-Saharan African populations are urgently needed. The combination of the well-known drugs chloroquine (CQ) and methylene blue (MB) is such a promising new regimen. However, there is some concern that MB could cause development of haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a condition which is prevalent in malaria-endemic regions. Against this background, 74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in northwestern Burkina Faso. Haemolysis did not occur, haemoglobin levels remained stable or even rose in the study participants, and the drug regimen was well tolerated. Therefore, standard dosages of MB appear to be safe in G6PD-deficient African populations with predominantly class III G6PD deficiency.

引用

页码：32 / 38

页数：7

共 34 条

[1]

Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8

[2] Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries [J].